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After BVS After KB inﬂation p
Proximal BVS area 7.481.73 7.951.99 0.03
AI at proximal stent 0.850.06 0.860.05 0.93
Before SB origin area
(mm2)
6.701.99 7.532.04 <0.01
AI before SB origin 0.810.08 0.800.07 0.88
After SB origin BVS area
(mm2)
6.031,76 5.891.67 0.77
AI after SB origin 0,850,06 0,820,07 0.04
Distal BVS area (mm2) 6.992,03 7,011,72 0.98
AI at distal BVS 0,840,06 0,840,05 0.71
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The appearance of jailed side branches post-procedure, at 6, 12, 24 and 36
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Background: Everolimus-eluting ABSORB Bioresorbable vascular scaffolds con-
sisted of poly-lactide are programmed to bioresorb approximately in three years. It is
still unknown how the struts implanted in front of a side branch behave during bio-
resorption. The purpose of this study was to assess the fate of bioresorbable struts
jailing side branch ostia at 6, 24 months (cohort B1) or at 12 and 36 months after
implantation of the BVS (cohort B2), with three-dimensional (3-D) optical coherence
tomography (OCT) reconstruction.
Methods: The ABSORB Cohort B trial is a multicentre single-arm trial to assess the
safety and performance of the BVS. Fourier domain-OCT pullbacks were obtained at
a pullback speed of 20 mm/s and 3-D rendering are computed. The area and the
number of strut-free compartments at side branch ostium delineated by the BVS struts
were evaluated. The endo- and abluminal coverages of the struts present at the ostium
of sidebranch were quantiﬁed at 6, 12, 24 and 36 month follow-up.
Results: Serial 3D-OCT images were available in total 26 side branches (13 in cohort
B1 and 13 in cohort B2). In the Cohort B1, the number of compartment and average
ostium area free from jailing struts did not change from baselines to 6 months, but
signiﬁcantly reduced from 6 months to 2 years. In the Cohort B2, there was similarly
a reduction of the number of compartments and the ostium area from baseline to one
year. However, from one year to 3 years, there was late enlargement of the sidebranch
ostium area (1Y: 0.470.64mm2, 3Y: 0.680.38mm2) without changing the number
of compartment. The thickness of the strut coverage was greater at the abluminal
surface compared to endoluminal strut side at followup.
Conclusions: The ostial area jailed by bioresorbable scaffold decreased up to 2 years
due to growing tissue between the struts, but late ostium area enlargement was
observed at 3 years.
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Background: In vitro and in vivo geometry of metallic single stent implantation in
coronary bifurcated lesions after kissing balloon (KB) intervention, has been well
studied. The same analysis of bioabsorbable vascular scaffolding (BVS) had not yetB12 JACC Vol 62/18/Suppl B j October 27–Novembeen reported. Our own in vitro observations with BVS showed integrity and no
device fracture after KB inﬂation when a 2.5 mm balloon diameter was inﬂated
through the struts.
Methods: In our series, 80 coronary bifurcated lesions were treated with provi-
sional BVS strategy. In 21 out of 80 lesions, we performed ﬁnal KB inﬂation after
BVS implantation. The reason for side branch (SB) intervention was ostial
angiographic stenosis (present before BVS implantation in 14 lesions, and
appearing after it in 7). IVUS studies were performed in 3 conditions: before
treatment, immediately after BVS and after KB inﬂation. Measurements were
performed at the proximal scaffold segment, before SB origin, under SB origin and
at the distal segment. This study analyzes the ultrasonographic (IVUS) ﬁndings
after BVS implantation and after KB inﬂation. For KB technique, the balloon
diameter inﬂated in the MV was always 0.5 mm minor than BVS diameter and the
SB balloon diameter was 2 or 2.5 mm.
Results: BVS diameter was 3.10  0.39 mm and the mean inﬂation pressure was
151 atm. The MV balloon diameter was 2.80.3 mm (0.5 mm minor than BVS
diameter in all cases). The SB balloon diameter was 2.30.2 mm and the inﬂation
pressure of both balloons was 7-8 atm. Integrity of the device was always observed
after KB. Good aposition of the proximal BVS and angiographic improvement of the
SB origin was always obtained. Geometry of the BVS may be modiﬁed after KB
technique, but nor distorted. The table summarizes the ﬁndings.Conclusions: Final KB inﬂation in bifurcated coronary lesions treated with BVS is
feasible, without inducing fracture or important distortion of the scaffold.
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Background: The aim of this study was to evaluate clinical outcomes of diabetic
versus non-diabetics patients when treated with the Absorb Bioresorbable Vascular
Scaffold (BVS) at 1-year follow-up.
Methods: This interim post-hoc analysis included 101 patients of the ABSORB
Cohort B trial and the ﬁrst consecutive 450 patients of the ABSORB EXTEND
trial with at least 1-year follow-up. These 2 trials had similar inclusion and
exclusion criteria; 136 diabetic patients were compared to 415 non-diabetic
patients. Primary end point was assessed by a composite of major adverse cardiac
events (MACE), including cardiac death, myocardial infarction, and target lesion
revascularization.
Results: There were no signiﬁcant differences in baseline patient demographics and
lesion characteristics between diabetic and non-diabetic patients treated with the
Absorb BVS, except for the prevalence of hypertension requiring medications
(75.0% in diabetics vs. 61.4% in non-diabetics, p¼0.004). The cumulative incidence
of MACE did not differ between diabetic and non-diabetic patients treated with the
Absorb BVS at 1-year follow-up (3.7% vs. 5.1%, p¼0.64). One patient out of 136
diabetic patients experienced deﬁnite late scaffold thrombosis (ST), whereas four ST
events (1 deﬁnite and 1 probable subacute ST, and 1 deﬁnite and 1 possible late ST)
were observed in the 415 non-diabetic patients. The incidence rate of deﬁnite/
probable ST was thus 0.7% in diabetic group and 0.7% in non-diabetic group
(p¼1.0).ber 1, 2013 j TCT Abstracts/ORAL/Bioabsorbable Vascular Scaffolds
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SConclusions: In this ﬁrst interim post-hoc analysis, diabetic patients treated with the
Absorb BVS showed similar incidence of 1-year MACE when compared to non-
diabetic patients.
TCT-37
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Background: Bioresorbable vascular scaffolds represent an exciting advance in
percutaneous coronary intervention (PCI), providing an initial coronary scaffold
which are eventually resorbed by the body. The DESolve Nx Bioresorbable
Coronary Scaffold System (BCSS) is a novel drug eluting bioresorbable scaffold
that combines a PLLA-based scaffold coated with a biodegradable polylactide-
based polymer and the drug Novolimus, a macrocyclic lactone mTOR inhibitor
which has demonstrated potent anti-proliferative properties in previous clinical
trials using Elixir's metallic Novolimus-Eluting (NE) coronary stents. The
DESolve NX study is a prospective, multicenter evaluation of the safety and
efﬁcacy of the DESolve Nx NEBCSS in patients with single de novo native
coronary artery lesions through clinical endpoints and multiple imaging
modalities.
Methods: 126 patients with single, de novo coronary artery lesions were enrolled in
this prospective, multi-centre, single-arm study. Those patients receiving the study
device are being analysed for multiple clinical endpoints including: Major Adverse
Cardiac Events (MACE), a composite endpoint of cardiac death, target vessel MI, or
clinically-indicated target lesion revascularization (CI-TLR); Clinically-indicated
Target Lesion and Target Vessel Revascularization, (CI-TVR) and Stent Thrombosis
assessed at 1, 6 and 12 months and annually to 5 years. All patients underwent
angiographic assessment at 6 months and a subset of patients underwent IVUS and
OCT assessment at 6 months and MSCT at 12 months.
Results: At baseline, the patient population had a mean age 62 years, 32% were
females, 21% were diabetic. Pre-procedure mean lesion length was 11.2 mm, RVD
was 3.06 mm. Serial QCA imaging at 6 months demonstrated low mean in-scaffold
late lumen loss (0.21mm.IVUS and OCT imaging indicated early vessel restoration at
6 months. Clinical events remained low (MACE ¼ 3.25% at 6 months) with no reports
of deﬁnite stent thrombosis.
Conclusions: The DESolve Nx NEBCSS demonstrated safety and efﬁcacy in
treating de novo coronary artery lesions with low clinical event rate and evidence of
low late lumen loss at 6 months. A ﬁrst report of results through 12 months will be
presented.TCT-38
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Background: In order to assess the intermediate term safety, clinical performance and
the bioabsorption process of the Paclitaxel-Eluting Bioabsorbable MagnesiumJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrScaffold (DREAMS) 3-year clinical data of cohort 1 and multi-modality imaging
outcomes are reported.
Methods: Forty-six subjects were enrolled in the ﬁrst-in-man BIOSOLVE-I study in
two different cohorts with clinical follow-up at 1, 6, 12, 24 and 36 months;
angiographic and IVUS follow-up for cohort 1 at 6-month and for cohort 2 at 12-
month. A subgroup of patients underwent OCT and vasomotion testing. The
primary endpoint is Target Lesion Failure (TLF) at 6-month for cohort 1 and at 12-
month for cohort 2. For some patients also 18-month and 24-month imaging data
are available.
Results: TLF rate at 24-month was 6.8% including 2 TLRs and 1 peri-procedural
MI occurring at the 12-month follow-up angiography; no events emerged from
12- to 24-month. No cardiac death or scaffold thrombosis was observed. 36-
month clinical data of Cohort 1 will be available upon presentation. Vasocon-
striction after acetylcholine at 6-month (Delta¼-10.04%; p¼0.0008 versus
baseline) followed by vasodilatation after nitroglycerine (Delta¼8.69%;
p<0.0001 versus baseline) demonstrates the uncaging aspect of the absorption
process with no further change at the 12-month follow-up. Six-month virtual
histology (VH) data showed a signiﬁcant decrease in the dense calcium by
39.5% (p¼0.0015) remaining stable from 6- to 12-month follow-up. This
decrease is interpreted as a surrogate assessment for the bioabsorption process of
the scaffold material. Preliminary echogenicity data using the decrease in
intensity of the ultrasound signal to quantify the change in strut structure
demonstrate a relatively large decrease of hyperechogenicity (28.5%) in the ﬁrst
6-month, followed by lower decrease (18.4%) in the 6 months thereafter, with
indications that the hyperechogenicity at 18-month returns to the values seen pre-
implantation.
Conclusions: DREAMS shows excellent safety and efﬁcacy data with no death and
no scaffold thrombosis up to 3 years in the BIOSOLVE-I trial. Multi-modality
imaging documented the absorption process and the uncaging aspect of this device
already at 6 months.TCT-39
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Background: ReZolve is a novel scaffold incorporating a unique slide & lock
expansion technology and a proprietary bioresorbable stent material that is
a polycarbonate co-polymer of tyrosine analogs. The aim of this study was to
evaluate, for the ﬁrst time, the safety and performance of the ReZolve siroli-
mus-eluting bioresorbable coronary scaffold in non-complex human coronary
lesions.
Methods: The RESTORE trial is a prospective, multi-center and multi-national trial
enrolling patients with single, de novo lesions in native coronary arteries with an
average reference diameter between 2.9 mm to 3.3 mm and lesion length up to 12
mm. The primary study endpoint was freedom from ischemic-driven target lesion
revascularization (TLR) at 6-months and 12-month in-scaffold late loss. Serial
IVUS evaluation (post procedure and at 12 months) was also performed in
a subgroup of patients. All imaging analyses were performed by independent core
labs.
Results: A total of 26 patients were enrolled in this trial and the device was
successfully implanted in 22 cases. Most patients were male (76%) and 36% of all
patients had diabetes. Mean reference vessel diameter and lesion length were 2.72 mm
and 11.1 mm, respectively. Acute recoil was minimal at 3.8%  6.7%. Through 6
months post-implant there were 2 focal in-scaffold TLRs. The 12-month QCA eval-
uation was completed for the ﬁrst 8 patients and resulted in a late loss of 0.20  0.19
mm. Of note, the mean stent diameter at implant in this initial group of patients was
2.94mm and remained constant over the 12-month follow-up period. The QCA and
safety data for the remaining patients as well as full IVUS assessment will be available
at the time of the meeting.
Conclusions: In this preliminary assessment, the ReZolve scaffold showed
excellent acute performance with minimal acute recoil. Complete 12-month
QCA and IVUS data is required to conﬁrm the performance of this novel
device.acts/ORAL/Bioabsorbable Vascular Scaffolds B13
